U.S. Markets open in 7 hrs 39 mins

CSPC PHARMA (1093.HK)


HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
11.32-0.02 (-0.18%)
As of 1:35PM HKT. Market open.

CSPC PHARMA

No. 226 Huanghe Street
Shijiazhuang 050035
China
86 31 1870 37015
http://www.cspc.com.hk

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees10,529

Key Executives

NameTitlePayExercisedAge
Mr. Dongchen CaiExec. Chairman, Chief Exec. Officer and Managing DirectorN/AN/A63
Mr. Weidong PanChief Accountant, Exec. Director and Director of Shijiazhuang Pharmaceutical Group Co. LimiteN/AN/A47
Mr. Kin Man ChakExec. DirectorN/AN/A51
Dr. Shunlong Wang Ph.D.Exec. DirectorN/AN/A53
Mr. Huaiyu WangExec. DirectorN/AN/A54
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

CSPC Pharmaceutical Group Limited, an investment holding company, manufactures and sells pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Antibiotics, Vitamin C, and Caffeine and Others segments. The company offers finished drugs, such as NBP series used for acute ischemic stroke; Oulaining series primarily for the treatment of mild to moderate memory and mental impairment resulting from vascular dementia, senile dementia, and brain trauma; Xuanning series to treat hypertension and angina pectoris; Duomeisu, a chemotherapy drug for lymphoma, multiple myeloma, and ovarian and breast cancer; Jinyouli for the prevention of leucopenia and infection induced by chemotherapy; Ailineng for nerve glioma and brain metastases, and adjuvant treatment of malignant pleural and peritoneal effusion; and Nuolining, a small molecule targeted cancer drug. It also provides generic drugs, including Qingre Jiedu, Ganmao Qingre, Yin Huang, Xiangsha Yangwei, and Huoxiang Qushu soft capsules; Zhongnuo Shuluoke injection; Guoweikang health supplement products; antibiotics, vitamin C products, and caffeine and other drugs; and traditional Chinese medicines. In addition, the company has 170 products under research and development with focus on the therapeutic areas of cardio-cerebrovascular, diabetes, oncology, neurology, and anti-infection. Further, it provides pharmaceutical research and development services; storage, sourcing, and distribution services; and sewage and pharmaceutical by-products, as well as trades in pharmaceutical products and holds properties. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was founded in 1997 and is headquartered in Shijiazhuang, the People’s Republic of China.

Corporate Governance

CSPC PHARMA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.